CN Bio
CN Bio is a UK organ-on-a-chip company that builds PhysioMimix microphysiological systems and contract research services for preclinical drug discovery.
- 58
- Cambridge, GBUnited Kingdom
CN Bio is a UK organ-on-a-chip company that builds PhysioMimix microphysiological systems and contract research services for preclinical drug discovery.
cn-bio.comCrawled Oct 16, 2026
In vivo models vs NAMs - address physiological, metabolic & immunological differences between animals & humans by using OOC in preclinical testing and research.
The page discusses calls to change the nomenclature for metabolic liver disorders from NAFLD to MASLD and debate over which term is best.
The article covers UK plans to phase out animal testing, CN Bio’s support for alternative methods, and PhysioMimix Core technology.
The company provides Organ-on-a-Chip resources, including webinars, application notes, scientific publications, and animations.
The page features Organ-on-a-chip news and articles and offers newsletter updates.
CN Bio lists life sciences job vacancies and provides information about careers at the company.
CN Bio Leadership team
The company says its team includes scientists, engineers, and creative thinkers working toward a shared vision.
332 Cambridge Science ParkMilton RoadCambridgeCB4 0WN
CN Bio describes PhysioMimix Core as predictive human organ models and assays for drug discovery.
CN Bio’s privacy statement says it is committed to protecting personal data.
CN Bio launches PhysioMimix Core, an organ-on-a-chip system that combines single-organ, multi-organ and higher-throughput configurations in one microphysiological platform.
Oct 2025CN BioNews article
CN Bio and Pharmaron form a long-term strategic partnership to develop organ-on-a-chip technologies, with Pharmaron validating CN Bio’s PhysioMimix technology and integrating organ-on-a-chip systems into its global R&D platform.
Apr 2025CN BioNews article
Organ-on-a-chip company CN Bio raises $21 million in the first close of its Series B investment round. The financing includes $10 million from Bayland Capital and $5.5 million from founding shareholder CN Innovations Holdings.
Apr 2024Drug Discovery WorldNews article
CN Bio and Altis Biosystems partner to integrate Altis’ RepliGut Planar-Jejunum model with CN Bio’s PhysioMimix Liver-on-a-chip. The integration supports a dual-organ microphysiological system for oral bioavailability studies. It brings the companies’ human gut and liver in vitro models together in one system.
Jan 2024CN BioNews article